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Sterol 14a-demethylases (CYP51) serve as pri-
mary targets for antifungal drugs, and specific
inhibition of CYP51s in protozoan parasites
Trypanosoma brucei (TB) and Trypanosoma
cruzi (TC) might provide an effective treatment
strategy for human trypanosomiases. Primary
inhibitor selection is based initially on the cyto-
chrome P450 spectral response to ligand bind-
ing. Ligands that demonstrate strongest bind-
ing parameters were examined as inhibitors of
reconstituted TB and TC CYP51 activity in vitro.
Direct correlation between potency of the com-
pounds as CYP51 inhibitors and their antipara-
sitic effect in TB and TC cells implies essential
requirements for endogenous sterol production
in both trypanosomes and suggests a lead
structure with a defined region most promising
for further modifications. The approach devel-
oped here can be used for further large-scale
search for new CYP51 inhibitors.
INTRODUCTION
Trypanosomatidae cause endemic infections and count-
less human deaths over the world (http://www.emedicine.
com/). Sleeping sickness, or African trypanosomiasis
(causative agent Trypanosoma brucei [TB]), and Chagas
disease, or American trypanosomiasis (Trypanosoma
cruzi [TC]), are most abundant. The parasites have com-
plex lifecycles using insects, tsetse fly (TB) and triatomine
bugs (TC), as vectors, humans, and a variety of mammals
as hosts. In humans, TB remains extracellular, the chronic
stage of the disease beginning when the pathogen
crosses the blood/brain barrier and invades the central
nervous system. TC affects the heart and gastrointestinal
tract and at the chronic stage is found mainly as an intra-
cellular amastigote. Currently 60 million people in Sub-Chemistry & Biology 14, 1283–129Saharan Africa are at risk of sleeping sickness, 0.3–0.5
million new cases occurring each year. Sixteen to eigh-
teen million people in Central and South America are
infected with TC with an annual incidence of 0.2 million
new cases. In the US, Chagas disease predominantly
exists as a result of immigration, blood transfusion, or or-
gan transplantation; however, autochthonous cases of the
infection have also been reported in several states [1–4].
There are no vaccines for these diseases and only a very
limited set of drugs; four for sleeping sickness (suramin
[since 1916], pentamidine [1941], melarsoprol [1949],
eflornithine [1990]) and two for Chagas disease (nifurtimox
[since 1972] and benznidazole [1978]) (Figure S1, see the
Supplemental Data available with this article online).
These drugs are inadequate because of high toxicity,
side effects, difficulties with administration, resistance,
and low or no efficacy at the prevalent chronic stages,
which are commonly fatal. New, more efficient medica-
tions for antitrypanosomal therapy are urgently needed
[1, 5–8].
One of the approaches for rational design of antitrypa-
nosomal drugs is to specifically block an essential enzyme
or metabolic pathway in the parasite. Being required in
most eukaryotic kingdoms, sterol biosynthesis is one
such possible target. The pathway leads to production
of cholesterol in mammals, ergosterol in fungi, and a vari-
ety of 24-alkylated and olephynated sterols in plants and
protists [9, 10]. Cholesterol, ergosterol, and sitosterol
(plants) are essential structural components of plasma
membranes. These structural sterols stabilize mem-
branes, determine their fluidity and permeability, and
modulate activity of membrane-bound enzymes and ion
channels. In addition, sterols serve as precursors for bio-
active molecules, which function at nanomolar hormonal
levels as regulators of cell cycle and development [10,
11]. While mammals can accumulate cholesterol from
the diet, blocking of ergosterol production in fungi is lethal;
it affects cytokinesis, stops cell growth, and eventually
leads to a collapse of the cellular membrane [9, 11]. Inhib-
itors of sterol biosynthesis are currently the most widely
used clinical and agricultural antifungal agents [12].3, November 2007 ª2007 Elsevier Ltd All rights reserved 1283
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Inhibition of Trypanosomal CYP51Positive results of use of inhibitors of fungal sterol biosyn-
thetic enzymes for potential treatment of protozoan infec-
tions have been obtained for TC [13–22] and Leishmania
species [23–25]. As for TB, it has been reported that
contrary to procyclic (insect) forms, bloodstream (mam-
malian) stages of the parasite lifecycle do not synthesize
endogenous sterols but use host cholesterol to build their
membranes [26, 27]. However, recent experiments have
demonstrated that inhibitors of fungal sterol 24-methyl-
transferase are effective in killing bloodstream forms of
TB [28, 29].
Sequencing of TB and TC genomes [7] revealed pres-
ence of all sterol biosynthetic enzymes in the parasites
including sterol 14a-demethylase (CYP51), a cytochrome
P450 that functions at the initial stages of the specific
postsqualene portion of the pathway, catalyzing a three-
step reaction of oxidative removal of the 14a-methyl group
from the newly cyclized sterol precursors [30]. CYP51 is
a primary target for azole derivatives in antifungal therapy.
Inhibition of the CYP51 reaction in fungi leads to accumu-
lation of 14a-methylated sterols, which are unable to
replace ergosterol in the membrane because of steric
hindrance [11].
CYP51s from TB and TC have only 25% amino acid
identity to their fungal orthologs and are 83% identical
to each other. We have shown that while TCCYP51
expresses preference towards the C4-dimethylated
24-methylenedihydrolanosterol, the natural substrate of
CYP51 from filamentous fungi, TBCYP51 is strictly spe-
cific toward the C4-monomethylated plant-like substrates
(obtusifoliol and norlanosterol) and that based on amino
acid sequence all other sequenced protozoan CYP51
will resemble the TBCYP51 in activity [31–33].
In this study, correlation between specific inhibition of
trypanosomal CYP51 and antiparasitic effect on trypano-
somal cells has been investigated. Using antifungal drugs
ketoconazole and fluconazole as controls, a selection of
fifteen novel imidazole derivatives from Novartis, found
to cause strong spectral responses in highly purified TB
and TC CYP51 (Kd[P450-azole] < Kd[P450-substrate]), were fur-
ther examined as inhibitors of reconstituted TB and TC
CYP51 activity in vitro. In accordance with binding param-
eters, the compounds produced a profound effect on the
initial rates of catalysis of both trypanosomal CYP51s. In
most cases, no excess of the inhibitor over the enzyme
was required to cause a 2-fold decrease in the rate of sub-
strate conversion. Time-course experiments, however,
revealed significant divergence in their potencies, often
contradicting the Kd values and suggesting that determi-
nation of an inhibitory potency as the influence onmaximal
CYP51 turnover can bemisleading.More detailed analysis
of azole structure/inhibitory effect relationship has shown
that while the presence of a bulky aromatic structure in
either a or b position relative to the imidazole ring is re-
quired for efficient binding, the azoles having an a-phenyl
group can be easily replaced by substrate in the reconsti-
tuted enzyme reaction. However, switching the phenyl
group to the b-position converts them into much more
potent CYP51 inhibitors, sometimes having virtually irre-1284 Chemistry & Biology 14, 1283–1293, November 2007 ª20versible action. Ketoconazole and selected experimental
compounds were further tested in TB and TC cells and
found to be effective growth inhibitors, cellular drug sensi-
tivities correlating with the long-term inhibitory effect
observed on CYP51 activity in vitro.
RESULTS AND DISCUSSION
CYP51 Spectral Response to Ligand Binding
as a Basis for the Initial Screening
By mechanism of action, azoles belong to the group of
reversible competitive inhibitors of cytochromes P450
[34]. The unsubstituted basic nitrogen forms the sixth
(axial) coordination bond with the heme iron blocking
binding and activation of molecular oxygen and prevent-
ing accommodation of the substrate in the active center.
The inhibitory effect strongly depends on the size and con-
figuration of the N-substituted part of the azole molecule,
which forms multiple additional interactions with the pro-
tein moiety of the cytochrome P450. Thus, the inhibitory
effect of small molecules such as imidazole or phenylimi-
dazoles is very weak, while much bulkier ketoconazole
serves as a potent antifungal drug but has rather low se-
lectivity; in addition to CYP51, it was also found to strongly
inhibit other human P450s [35].
Being highly hydrophobic, membrane-bound enzymes
metabolizing substrates of extremely low solubility in
aqueous solutions, fungal CYP51s are quite resistant to
purification (so far, purification of only three fungal
CYP51 orthologs was reported [30]) and also often to re-
constitution of activity in vitro. Because of these problems,
inhibitory potencies of azole drugs are mainly compared
indirectly as their effects on fungal strain growth (e.g.,
[11, 36–39]). Though not normalized per equal amount of
P450, the data imply that potencies of the same azole
on CYP51s from different fungal species can vary signifi-
cantly, differences up to three orders of magnitude have
been reported [11, 34]. The latter means that highly selec-
tive strong CYP51 inhibition can be potentially reached as
a result of maximal correspondence between the struc-
ture of an azole derivative and the topology of the target
P450 substrate binding cavity. The needs for selective
CYP51 inhibitors are growing sharply because such com-
poundswould increase the efficiency and shorten the time
necessary for treatment, which in turn can prevent the de-
velopment of drug resistance, which is one of the most
severe problems in clinical antifungal therapy (especially
in treatment of immunocompromised patients) and in
agriculture [40].
As a cysteine-coordinated hemoprotein, sterol 14a-
demethylase responds spectrally to any perturbations in
the area surrounding the heme iron (Figure 1). These spec-
tral responses, type 1 for the interaction with the substrate
and type 2 for interaction with an azole inhibitor, can be
used to estimate the apparent dissociation constants
(Kd) of the enzyme/ligand complexes. Thirty imidazole de-
rivatives from aNovartis program on inhibitors of vitamin D
hydroxylases [41, 42] were tested for spectral responses
in highly purified TB and TC CYP51. Eleven compounds07 Elsevier Ltd All rights reserved
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Inhibition of Trypanosomal CYP51Figure 1. CYP51 Absorbance upon Alter-
ations in the Heme and Its Environment
Main panel, absolute spectra of 2 mM
TBCYP51: oxidized ligand free (red), reduced
ligand free (green), oxidized 47% high-spin
obtusifoliol bound (cyan), azole 4 bound
(black). Blue shift in the Soret band maximum
(from 417 to 394 nm) is caused by expulsion
of a water molecule from the sixth coordination
sphere of the heme iron (e.g., by substrate,
which itself does not form a coordination
bond with the iron). This spectral response
(type 1) reflects transition of the iron from the
hexa-coordinated low-spin state to the
penta-coordinated high-spin state. Direct
coordination of a basic atom (e.g., aliphatic or
aromatic nitrogen) to the heme iron causes
a red shift in the Soret band (to 426–429 nm)
also known as type 2 response in the difference
spectra. Right inset, type 2 difference spectra
observed upon azole binding to oxidized,
reduced, and substrate-bound TBCYP51
(color code as above). Left inset, coordination
of fluconazole to the heme iron in the crystal
structure of the CYP51 from Mycobacterium
tuberculosis [1ea1]. The iron is shown as brown
sphere, the heme-coordinated Cys residue
(fifth axial ligand) is located beneath the iron,
the sulfur atom is colored in yellow, protein
moiety is shown in grey.(Figure 2A) demonstrated high binding affinities (the Kds
being close or lower than the Kds calculated from type 1
spectral responses of TB and TC CYP51 to their sub-
strates) and were chosen for further testing as potential in-
hibitors. Antifungal drugs ketoconazole and fluconazole
served as controls. Supporting the notion that the affinities
of azole/CYP51 interactions can be species specific, the
estimated apparent Kd of these compounds to the proto-
zoan CYP51s are often more than one order of magnitude
lower than the values obtained for the CYP51 fromMyco-
bacterium tuberculosis (26% amino acid identity) and in
many cases significantly lower than those calculated for
the human ortholog (27% identity to TB/TC CYP51) (Table
S1). Comparing the Kds calculated for the two trypanoso-
mal CYP51s, only compounds 1, 11, and especially keto-
conazole show higher affinity toward the TC ortholog, the
rest of the azoles produce rather similar Kds in both en-
zymes, the best values (compounds 4 and 10) being
20-fold lower than the Kds for the interaction of TB and
TC CYP51 with their substrates.
Identification of the Most Potent CYP51 Inhibitors
Estimation of the Inhibitory Potency
in the Reconstituted Enzyme Reaction In Vitro
In accordance with their high binding affinity, the com-
pounds produced strong inhibitory effect on the initial
rates of catalysis. The molar ratios inhibitor/enzyme re-
quired to slow down the reaction 2-fold (I/E2) were lower
than one in all cases except for compound 5 (for both try-
panosomal CYP51s), ketoconazole, and fluconazole for
the TB ortholog (Figure 2).Chemistry & Biology 14, 1283–129The reaction conditions used to reconstitute the CYP51
activity are optimized to give maximal turnover and repro-
ducibility [30]. Low solubility of the sterols limits maximal
substrate concentration to 50 mM, while decrease in the
enzyme concentration affects stability and protein-protein
interactions with the electron donor, cytochrome P450
reductase. Because of these restrictions, time-course ex-
periments were undertaken to increase sensitivity of the
assay in order to distinguish the most potent inhibitors.
The results revealed significant divergence in the poten-
cies of the compounds assayed. However, I/E2 deter-
mined as the molar ratio inhibitor/enzyme required for
reaching a 2-fold decrease in the substrate conversion
per 1 hr often demonstrated lack of correspondence
with the relative apparent Kd values (Figure 2, numbers
in brackets). Though certain increase in the I/E2 ratios es-
timated for long-term incubationswasexpected as a result
of substrate depletion, no such changes were registered
for compounds 2 and 4. Stronger inhibitory effect than
could be predicted from the Kd was demonstrated by 1,
especially on TBCYP51. On the contrary, compounds
6–10, regardless of the variations in their Kds, all show a
similar rapid time-dependent increase in the I/E2.
Clearly the best inhibitors are distinguished over time
upon comparison of the effects of the azoles at equimolar
ratio to the enzymes (Figure 3). Under this condition, no
substrate conversion can be detected even after 1 hr reac-
tion when compounds 2 or 4 are added. Incubation inter-
vals up to 4 hr were testedwith the same result, whilemore
than 90% of the enzyme in the reaction remains in the
active P450 form. Thus, within the time tested, the effect3, November 2007 ª2007 Elsevier Ltd All rights reserved 1285
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Inhibition of Trypanosomal CYP51Figure 2. Azole Derivatives Assayed as Potential Inhibitors of TB and TCCYP51
(A) Compounds selected basedon the binding affinities estimated from the P450 spectral responses. The compounds used in cellular studies aremarked
with grey background. Asterisk, apparent dissociation constants, mM. Inhibitory effects of azoles with Kds higher than the Kds for the enzyme/substrate
complexes (1.2 and 0.8 mMfor the interaction of TBCYP51with obtusifoliol and TCCYP51with 24-methylenedihydrolanosterol, respectively [31, 32]) were
muchweaker; compound 5 is included as an example. Double asterisk, molar ratio inhibitor/P450which produces a 2-fold decrease in the activity. Triple
asterisk, I/E2 calculated as the influence on the initial rate (5
0) of catalysis (I/E2 calculated as the influence on the percentage of substrate conversion after
1 hr [600] reaction). The results of four experiments are presented as mean; standard deviation does not exceed 10%.
(B) Azoles added after structure/activity relation analysis.of compounds 2 and 4 on both trypanosomal CYP51s
remains irreversible.
The Affinity of the Azole-CYP51 Interaction Can
Change under the Reaction Conditions
To understand the reasons for the observed discrep-
ancies between the apparent Kds and inhibitory effects
on the CYP51 activity, we tested stability of compounds
4 (long-term inhibitor) and 10 (short-term inhibitor) in the
reaction mixture and compared influence of substrate
and P450 reduction on the relative affinities of their inter-
action with TBCYP51 (spectral responses of substrate-
bound and Na2S2O4-reduced TBCYP51 to the azole bind-
ing are shown in Figure 1, insert). No trace of metabolism1286 Chemistry & Biology 14, 1283–1293, November 2007 ª20or decomposition during the reaction time was detected
for either azole. Excess of substrate, however, was found
to result in a 13-fold higher increase in the calculated Kd
upon titration of TBCYP51 with 10 than upon titration
with 4 (Table 1). If the substrate was added after the azole,
it did not cause spectral changes when TBCYP51 was
bound with 4 but produced time-dependent type 1 re-
sponse in the case of 10. A negative effect of P450 reduc-
tion on the interaction with 10 was also stronger, 4-fold in-
crease in the apparent Kd versus only 1.5-fold increase in
the case of compound 4. Again, if TBCYP51 was reduced
after the titration with the azoles and then exposed to CO,
the rate and efficiency of the CO-complex formation [43]07 Elsevier Ltd All rights reserved
Chemistry & Biology
Inhibition of Trypanosomal CYP51Figure 3. CYP51 Activity at 1:1 Molar
Ratio Inhibitor/Enzyme
The substrates are added at 50-fold molar
excess. The results are presented as mean;
standard deviation (SD) did not exceed 10%.
Inhibitor numbers and letters refer to com-
pounds in Figure 2.indicated that the heme-coordinated imidazole nitrogen of
compound 10 is much more easily replaced by CO from
the iron coordination sphere.
One explanation of the data is that the affinity of azole-
CYP51 interaction in the reaction mixture can be altered,
the expression of the differences depending on the inhib-
itor structure. The number of contacts between the azole
molecule and the enzyme substrate binding cavity might
be decreased as a result of protein conformational dy-
namics upon substrate recognition, interaction with the
reductase, electron transfer, and subsequent reduction
so that inhibitors such as 10 can be more easily released
from the active center. An alternative explanation can be
connected with the fact that binding of some inhibitors
alone is known to cause conformational changes in
P450s [44]. By tightening the complex, such changes
might impede protein dynamics and thus make the inhib-
itory effect much stronger, for example as with 4. To sum-
marize, being a useful tool in the primary search for bind-
ing ligands, spectral response of substrate-free oxidized
P450 may not truly reflect the relative affinity of the inter-
action under the reaction conditions. Prediction of the
inhibitory potency relying solely on binding parametersChemistry & Biology 14, 1283–12or IC50 values determined as the influence on the initial
rate of reaction (especially without considering P450 con-
centration) can be misleading. Long-term inhibitory effect
appears to be most informative for identification of stron-
gest CYP51 inhibitors.
Azole Structure/Activity Relationship
The two strongest TB and TC CYP51 inhibitors (2 and 4)
(Figure 2A) differ in composition of the substituents at the
d-position relative to the imidazole, yet both contain a phe-
nyl ring at the b-position. The inhibitory effect of the levoro-
tatory enantiomer of 2 (compound 3) is slightly weaker, but
the I/E2 ratios after extended incubation with CYP51 still
remain less than 1. On the contrary, in all inhibitors that re-
vealed sharp time-dependent increase in the I/E2 values
(5–10) the phenyl group is present at the a-position. Be-
cause structurally the a-phenyl compounds differ only in
the composition on the d-substituents, influence of these
differences on the apparent binding affinity can be easily
seen. While a short five-member heterocycle of 5 is clearly
insufficient to provide efficient binding, bulkier constitu-
ents (6–10) produce better Kd values. When this part of
themolecule consists of two aromatic rings with rigid con-
nection (6, 7), the calculated affinities remain moderate,Table 1. Modification of Azole-Binding Properties upon Substrate Binding or Heme Reduction and Replacement
of the Bound Azoles by Substrate or Carbon Monoxide
Selected
Azoles
Apparent Kd, mM Replacement
by Substrate
(% of high-spin form)
Replacement by CO
(versus no inhibitor), %b
Oxidized,
No Substrate
Oxidized, Plus
Substratea
Reduced, No
Substrate
Rate
(per minute) Maximum
4 0.05 ± 0.003 0.17 ± 0.02 (3[) 0.07 ± 0.01 (1.6[) - 6 ± 0.7 52 ± 7
10 0.05 ± 0.002 2.2 ± 0.44 (44[) 0.26 ± 0.02 (4[) + (34 ± 0.7) 13 ± 0.8 95 ± 6
aObtusifoliol, 20mM (azole titration range 0.2–10 mM).
b The spectra are shown in Figure S2. The results of two experiments are presented as mean ± standard error.93, November 2007 ª2007 Elsevier Ltd All rights reserved 1287
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Inhibition of Trypanosomal CYP51butwhen the connection is flexible (especially 9 and10) the
Kds become very low, the best values (0.05 mM) being as
goodas thoseobtained for compound4. Perhaps flexibility
of this part of the azole molecule leads to its easier entry
into the CYP51 substrate binding cavities, but similar to
theothera-phenyl azoles, it still lacks restraining interactions
necessary to prevent the inhibitors from being replaced
by the substrate upon catalysis. On the other hand, com-
pounds 1 and 11, having a-substituents more bulky than
a single phenyl ring, produce long-term inhibitory effects
stronger than 5–10 (Figure 2A). In addition, these two
azoles demonstrate some selectivity. Compound 1 (two
phenyl rings at the a-position) is a little more favorable for
TBCYP51,while for TCCYP51, the longer armof the benzyl
group (so that benzene and imidazole rings remain sepa-
rated by two C atoms) of 11 is preferable.
Figure 4. Growth and Inhibition of TB
(A) Sensitivity of Alamar Blue assay tomonitor viable TB cells: the ratios
between fluorescence emission in growing cells (signal) and in the
growth media (noise) at increasing plating densities of procyclic and
bloodstream TB. Error bars represent SD.
(B) Cellular responses to the CYP51 inhibitors (1, 5, 10, 20, 30, and
50 mM) BS, bloodstream TB, PC, procyclic TB, HL60, human leukemia
cell line. Effects of the compounds on the Alamar Blue absorbance
spectra are shown in Figure S4.1288 Chemistry & Biology 14, 1283–1293, November 2007 ª20Modification of a Basic Structure
Because any drug development process can face prob-
lems such as cytotoxicity, cell permeability, solubility,
rapid turnover in plasma, insufficient life-time, etc., it is
important to be able to predict the most promising direc-
tions for further modifications of a lead structure. To ver-
ify the importance of the phenyl group location at the
b versus the a position, the a-phenyl isomer of 4 (com-
pound 12) (Figure 2B) was tested and, in correspondence
with our predictions from compounds 6–10, regardless
of its strong apparent binding affinity, showed a rapid
decrease in the inhibitory effect over time. Influence of
alteration in the composition of the b-substituent was
investigated with an additional set of eight derivatives
of compound 4. The inhibitory effects were compared as
inhibition of CYP51 activity at 1:1 molar ratio azole/P450
after 5 and 60 min reaction, and quite significant differ-
ences in their potencies were observed (Figure S3). Two
of these compounds (17 and 19) (Figure 2B), revealed in-
hibitory effects as strong as 4 and were included in further
studies.
Correlation between CYP51 Inhibition
and Antiparasitic Effect
Cellular Responses in the Mammalian
and Insect Life Stages of TB
Only two of four clinically available drugs (melarsoprol and
eflornithine [Figure S1]) can treat late stages of sleeping
sickness. However, eflornithine is only efficient for TB
gambiense, and melarsoprol is extremely toxic, causing
severe, often fatal encephalopathy, and has up to 30% re-
sistance in parts of central Africa. Suramin and pentami-
dine do not penetrate the blood/brain barrier and can treat
only the first, hemolymphatic stage of the disease, which
sometimes passes unnoticed because of nonspecific
symptoms. Recently quite promising data on use of
nitroimidazoles as possible drug candidates for African
trypanosomiasis have been reported [46], yet the target
for these compounds has not been determined. Though
major sterol components identified in bloodstream TB
most likely originate from host cholesterol [27], it is not
excluded that the parasite might still require functional
sterols, for which hormonal level of action can be below
routine sterol detection limits. We aimed to clarify this
issue by comparison of the effects of potent TBCYP51 in-
hibitors in bloodstream and procyclic (known to synthe-
size endogenous sterols [27, 47]) cells of TB.
The Alamar Blue method was adjusted to monitor TB
cell growth. While the procyclic form, though growing
slowly at low concentrations provided very good fluores-
cent signal starting from plating density of 106 cells/ml
(Figure 4A) for the bloodstream TB originally cultured in
the commonly used HMI-9 medium [48], the signal/noise
ratios remained below 2 and rapidly dropped over time
with increase in the cell densities. Using absorbance
spectroscopy, we have observed that several compo-
nents of the HMI-9 themselves cause fast Alamar Blue re-
duction and that the bloodstream TB can further convert
the reduced (fluorescent) dye into its colorless hydroxy07 Elsevier Ltd All rights reserved
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Inhibition of Trypanosomal CYP51Table 2. Sensitivities of Trypanosomal Cells to CYP51 Inhibitors
CYP51
Inhibitor
TB Testing System TC Testing System
ED50, mM
a
Selectivity
Indexb
Trypomastigotes Amastigotes
Procyclic
TB
Bloodstream
TB HumanHL60 ED50, mM
Inhibition at
1 mM, % ED95, mM
Inhibition at
1 mM, %
Kc 18 16 29 1.8 ntd - - -
2 7 1.3 >50 >38 <1 78 <1 99
4 4 2.5 >50 >20 <1 72 <1 97
10 20 8 4 0.5 8 7 20 43
17 1 1.3 20 15 nt - - -
19 5 1.5 22 15 <1 92 <1 99
The values were calculated from the dose-response curves.
a The dose causing a 50%cell growth inhibition, ED50 < 10 mMbeing proposed as a threshold to consider a compound as a potential
antisleeping sickness drug [45].
b ED50(HL60)\/ED50(bloodstream TB).
c Ketoconazole.
dNot tested.form [49]. To overcome this problem, several different cell
culture media were tested, and RPMI 1640 found to com-
bine both requirements, support bloodstream TB growth
and maintain the dye in the oxidized nonfluorescent
form, was used in further experiments.
All the azoles demonstrated clear dose-dependent in-
hibitory effect on both procyclic and bloodstream TB
(Figure 4B). Among them, ED50 above 10 mM for blood-
stream TB was obtained only for ketoconazole (35% and
37% responses for procyclic and bloodstream TB,
respectively, with less than 10% negative influence on
human HL60). At increasing ketoconazole concentration,
inhibition of human cells becomes more pronounced, se-
lectivity index human/bloodstream TB being 1.8 (Table 2).
This low selectivity is not surprising for ketoconazole since
the drug is known to inhibit growth of cancer cells and has
been used for a long time in cancer chemotherapy [50, 51].
Though stronger effect of 10 in bloodstream versus procy-
clic TB (8 and 20 mM, respectively) may reflect slower ste-
rol flow (which means lower concentration of the CYP51
substrate) in the mammalian form of the parasite, most
likely a large portion of sensitivity of the TB cells to 10
might result from general cytotoxicity of the compound
unless the effect on HL60 is cancer cell specific. The
best antitrypanosomal activity is provided by the four
strongest CYP51 inhibitors, compounds 2, 4, 17, and 19.
At 10 mM concentration, these azoles cause more than
90% growth inhibition of bloodstream TB, three of them
produce ED50 below 2 mM. The observed direct correlation
between the potency of the tested azoles as CYP51 inhib-
itors and their antiparasitic effect both in insect and mam-
malian stages of the TB lifecycle indicates that CYP51
reaction is essential in the bloodstream form of the para-
site and thus supports the notion [10] that sparking sterols
may play an important role in Trypanosomatidae. High se-
lectivity of compounds 2, 4, 17, and 19 for trypanosomalChemistry & Biology 14, 1283–129cells makes them good candidates for further testing as
potential antitrypanosomal agents.
Effect on TC: Bloodstream Trypomastigotes
and Intracellular Amastigotes
Both clinical drugs currently available for treatment of TC
infections (benzinidazole and nifutrimox [Figure S1]) are
effective only for the early stages, intracellular forms of
TC being more difficult targets. Because human stages
of TC are known to synthesize endogenous sterols with
the major component being the final sterol product of
the fungal pathway, ergosterol, azole derivatives were
tested as potential anti-TC agents. Some of them were
found effective and are considered for clinical trials
[18–20]. However, specific inhibition of the target enzyme
has never been investigated.
Potent TCCYP51 inhibitors produce profound antipara-
sitic effect on TC (Figure 5 and Table 2). The ability of try-
pomastigotes to infect heart cells after exposure to 1 mM
concentration of 2, 4, and 19 was decreased by 78%,
72%, and 92%, respectively (Figure 5A, lower panel).
Only for compound 10 (short-term TCCYP51 inhibitor)
8 mM concentration was required to reach 50% inhibition.
Most remarkably, the compounds strongly inhibit multipli-
cation of amastigotes within cardiomyoblasts, ED95 being
less than 1 mM for 2, 4, and 19 (inhibition at 1 mM 99%,
97%, and 99%, respectively) as seen in Figure 5A, upper
panel, and microscopically observed in Figure 5B, sug-
gesting their potential applicability to be used for treat-
ment of currently incurable late stages of the disease.
Alterations in the sterol composition of TC cells upon
treatment with compound 2 (sharp decrease in the ergos-
terol formation and accumulation of the C14 methylated
precursors 24-methylenedihydrolanosterol and lano-
sterol) (Figure 5C) provide direct evidence that the mode
of action of the compound is connected with CYP51
inhibition.3, November 2007 ª2007 Elsevier Ltd All rights reserved 1289
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Inhibition of Trypanosomal CYP51Figure 5. Exposure of T. cruzi Trypomastigotes to CYP51 Inhibitors Dramatically Inhibits T. cruzi Multiplication within Cardiomyo-
cytes and the Percentage of Cellular Infection
(A) Potent inhibition of both T. cruzi intracellular multiplication and infection in cardiomyoblasts by CYP51 inhibitors. Trypomatigotes were pretreated
with several concentrations of CYP51 inhibitors 2, 4, 10, and 19 or mock treated, exposed to cardiomyoblasts monolayers, and T. cruzimultiplication
was evaluated at 72 hr by determining the number of T. cruzi/cell (upper insert) and the percent of infection (lower insert). The data represent the
mean ± SD of results from triplicate samples. SD did not exceed 10% of the mean.
(B) Microscopic observation of the inhibition of T. cruzimultiplication by 1 mMCYP51 inhibitors within cardiomyoblasts at 72 hr. T. cruzi pretreated with
control DMSO showed high levels of parasite multiplication, whereas cells exposed to trypanosomes preincubated with 1 mM azoles showed dra-
matic decrease in the number of intracellular parasites.
(C) TLC analysis of sterol composition of TC cells. Sterol standards: 24-methylenedihydrolanosterol (M), lanosterol (L), obtusifoliol (O), cholesterol (C),
and ergosterol (E), 5 nmoles each (lane 1). Sterols from 10mg of cell pellet of untreated epimastigotes (lane 2) and epimastigotes incubated for 120 hr
with compound 2 (lane 3). The results of GC-MS analysis of TC sterols are provided in Table S2.SIGNIFICANCE
Because TB species contain only two CYP genes, en-
coding CYP51 and a putative P450 of unknown func-
tion (http://www.tigr.org/), antiparasitic effect of
potent CYP51 inhibitors in TB must be directly con-
nected with disturbances in sterol 14a-demethylation.
Comparable sensitivities of bloodstream and pro-
cyclic TB to the TBCYP51 inhibitors imply that the
CYP51 gene is active in the mammalian stages of the
parasite lifecycle and thus support the notion [29]
that, similar to plants/algae, biologically active (func-
tional) sterols of endogenous nature must be essential
in Trypanosomatidae. This finding suggests that
CYP51 inhibitors should be included in testing as
potential antisleeping sickness agents and that the
nitroimidazoles, recently found to be potent in killing
bloodstream TB [46], might actually target TBCYP51.
Supported by the profound effect of the most potent
TCCYP51 inhibitors both in trypomastigote and intra-
cellular human stages of TC, the work offers a novel
lead structure with a defined region most promising
for possible further modifications for antitrypano-
somal therapy. Taking into account high amino acid
sequence identity between the CYP51s from Trypano-1290 Chemistry & Biology 14, 1283–1293, November 2007 ª20soma and Leishmania (74%–78%) there is a high prob-
ability that the same compounds will be effective
against leishmaniasis, which might be of vital impor-
tance for visceral forms of the disease as many azoles
are known to penetrate the blood/brain barrier [52].
The approach undertaken in this study including
large-scale spectroscopic screening for binding li-
gands and quantification of the inhibitory potencies
in the reconstituted enzyme reaction followed by test-
ing the best compounds in the parasite cells is prom-
ising to follow for the discovery of new, rationally
designed antiprotozoan drugs and perhaps novel
antifungal agents as well.
EXPERIMENTAL PROCEDURES
Overexpression of TB and TC CYP51 in E. coli, purification to electro-
phoretic homogeneity, and reconstitution of enzymatic activities with
3H-labeled sterol substrates were performed as previously described
[31, 32]. Experimental azole derivatives and their further modifications
were a generous gift fromNovartis Research Institute (Vienna, Austria);
the Novartis numbers for the compounds are: 1, SDZ-89443(), 2,
SDZ-284692(+); 3, SDZ-284693(); 4, SDZ-285604(); 5, SDZ-
287113; 6, VAB251(R); 7, VAB309(R); 8, SDZ-287115; 9, VAB636(R);
10, VAB635(R); 11, SDZ-285936; 12, SDZ-285428(S); 17, SDZ-
284531; 19, SDZ-284797(+); 20, SDZ-284798().07 Elsevier Ltd All rights reserved
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Azole-induced spectral changes in TC and TBCYP51 (2 mM)weremon-
itored in 2 ml tandem cuvettes in the wavelength range 350–500 nm
with a Shimadzu UV-2401PC spectrophotometer. The azoles were
dissolved in DMSO (1mM) and added in the range 0.2–20 mM.Maximal
spectral response per nanomole of P450 (DA426–410 for oxidized sub-
strate free, DA426–390 for oxidized CYP51 in presence of substrate,
and DA424–445 for reduced, substrate-free CYP51) and apparent Kd
were determined from the equilibrium titration curves (Figure 1, insert)
by plotting absorbance changes against the concentration of free
ligand and fitting the data to a rectangular hyperbola with SigmaPlot
Statistics [53]. Replacement of the azoles by sterol substrate and by
carbon monoxide after the titration experiments was monitored as
type 1 spectral response and as CO binding spectra, respectively.
Inhibition of CYP51 Activity
Equal volumes of the reaction mixture containing 1 mM P450, 2 mM TB
cytochrome P450 reductase, 50 mM obtusifoliol for TBCYP51, and
24-methylenedihydrolanosterol for TCCYP51 were added to the
tubes with the azole inhibitors (final concentration 1–100 mM), and
the reaction was initiated with the addition of NADPH. For time-course
measurements, aliquots of the reaction mixture were taken over time.
The sterols were extracted with ethyl acetate and analyzed by reverse
phase HPLC equippedwith b-RAM radioactivity flow detector by using
Nova-Pak C18 column. Reverse phase HPLC with 0.05 M disodium
hydrogen orthophosphate/acetonitrile (50:50 v/v) adjusted to pH 6.0
with glacial acetic acid as the mobile phase and UV detection at
230 nm was employed to confirm stability of the azoles in the solution
during the reaction. CO-spectra of the control (no inhibitor) sample
were taken to confirm stability of the P450s. The inhibitory potencies
of azoles were compared upon time course measurements as I/E2
(molar ratio inhibitor/enzyme at which the substrate conversion
decreases 2-fold) and as percentage of inhibition at molar ratio 1:1.
Cell Culture and Growth Inhibition Assay for TB
The procyclic forms of the TB cell line 29-13 were grown in SDM-79
medium (JRH Biosciences, Lenox, KS) supplemented with 10%
heat-inactivated fetal bovine serum at 27C [54]. Bloodstream forms
of the TB cell line SM427 [48] and human myeloid leukemia cells
HL60 (DSZM, Braunschweig, Germany) were grown in RPMI 1640 me-
dium supplemented with 10% heat-inactivated fetal bovine serum at
37C. Both cultures were maintained in a humidified atmosphere con-
taining 5% CO2. Cell counting was done with a Neubauer haemocy-
tometer. The cells were seeded at various densities (1052 3 106/ml)
in 24-well plates and incubated for 48 hours. The cell viability indicator
Alamar Blue (Biosource, USA) was added to final concentration of
10%, and after 2 hr of additional incubation, 200 ml aliquots were
placed into 96-well flat bottom microtiter plates (Costar, USA), and
fluorescence was measured at 520 nm excitation wavelength and
590 nm emission wavelength by using a FLUOstar Optima plate reader
(BMG Lab Technologies, Germany). Cell viability was monitored as
emission in the cells versus emission in the growth media (signal-to-
noise ratio). Plating cell densities of 106 for the procyclic forms and
5 3 105 for the bloodstream forms of TB and for human HL60 (sig-
nal-to-noise ratios 12, 6, and 4.5, respectively) were selected for fur-
ther measurements. Reduction of Alamar Blue in the cells, absence
of media-induced reduction or further conversion into the hydro
form were confirmed by absorbance spectroscopy in the range of
400–700 nm (the spectra are shown as Figure S4). To evaluate the
growth inhibition effect, the cells were incubated in the presence of
CYP51 inhibitors (0–50 mM), the antisleeping sickness drug suramin
(bloodstream TB), and NaN3 (procyclic TB). Wells containing cells,
medium, and 1% DMSO alone served as controls. The concentrations
causing 50% growth inhibition (ED50, 50% effective dose) were calcu-
lated from dose-response curves. The selectivity of the inhibitors for
the parasite cells was estimated as ratio ED50 (human HL60)/ED50
(bloodstream TB) [45].Chemistry & Biology 14, 1283–129Growth and Inhibition of TC
Trypomastigotes (106 organisms) were pre-exposed to the CYP51 in-
hibitors 2, 4, 10, and 19 dissolved in DMSO/DMEM at several concen-
trations (1–50 mM) or to control DMSO/DMEM for 30min. The parasites
were then exposed in triplicate to rat cardiomyocyte monolayers at the
ratio 10 parasites/cell in Lab Tech chambers for 2 hr as described [55].
After removing the unbound parasites, monolayers were incubated
with DMEM supplemented with 10% FBS for 72 hr to allow parasite in-
tracellular multiplication and the number of T. cruzi per 200 cells, and
the percent of infection were microscopically determined in Giemsa
stained monolayers [55].
TLC and GC-MS Analysis of TC Sterols
Epimastigotes (plating density 107 cells/ml) were cultured in brain heart
infusion supplemented with hemin and 10% calf serum for 120 hr with-
out an inhibitor and in the presence of compound 2. The inhibitor was
added daily to maintain 1 mM concentration for the first 3 days, and
2 mM concentration for the last 2 days. The cell pellet was washed
with Hank’s balanced salt solution without phenol red to remove ex-
cess of cholesterol from the serum and saponified by using 10%
KOH in 98% aqueousmethanol at reflux temperature for 1 hr. The neu-
tral lipids obtained by dilution with water and extraction with hexane
were subjected to silica gel TLC plates (0.25 mm, Whatman, Germany)
for 30min in hexane:ethyl acetate (8:2) as developing solvent andmon-
itored in an iodine chamber. Individual sterols were identified by using
a GC-MS apparatus with Hewlett-Packard LS 6500 gas chromato-
graph interfaced to a 5973mass spectrometer as described previously
[29].
Supplemental Data
Supplemental Data include binding of the azoles to the CYP51 ortho-
logs from human andMycobacterium tuberculosis, list of clinical drugs
currently used for antitrypanosomal therapy, CO-binding spectra of
TBCYP51 in the presence and in the absence of inhibitors 4 and 10,
inhibitory effects on the CYP51 activity of the compounds obtained
upon structure 4 modification, absorbance spectra of Alamar Blue
upon reduction by TB cells, and GC-MS data on sterol composition
of TC cells grown in the absence and in the presence of compound
2 and are available at http://www.chembiol.com/cgi/content/full/14/
11/1283/DC1/.
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